Table 1.
Status of current clinical development of novel, targeted drugs in CLL
PO indicates per ora (orally); TLS, tumor lysis syndrome.
*Analysis included only fludarabine-refractory patients.
†60% showed nodal responses without a 50% reduction of lymphocyte counts.